<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mosely, Mary</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Sasamura, Hiroyuki</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">STAR CAST: Preliminary Results of Trial to Regress Hypertension</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2013-07-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">6-6</style></pages><abstract><style  face="normal" font="default" size="100%">Results from animal models have shown that hypertension can be regressed to normal blood pressure (BP) levels [Smallegange C et al. Hypertension 2004] and that this reduction can be maintained after pulse treatment with an angiotensin receptor blocker [Ishiguro K et al. Hypertension 2009]. The Short Treatment with Angiotensin Receptor Blocker Candesartan Surveyed by Telemedicine study [STAR CAST; Sasamura H. Hypertens Res 2008; UMIN-CTR UMIN000000941] tested the feasibility of regressing hypertension in humans.</style></abstract><number><style face="normal" font="default" size="100%">9</style></number><volume><style face="normal" font="default" size="100%">13</style></volume></record></records></xml>